17 /100
LOW RISK
Score updated Jul 14, 2026

DYN — Dyne Therapeutics, Inc. Dilution Risk Tracker

Track DYN dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track DYN — Get alerts when the score changes →

As of July 14, 2026, Dyne Therapeutics, Inc. (DYN) has a DilutionWatch DilutionScore of 17/100, rated LOW dilution risk. Dyne Therapeutics, Inc. has a market capitalization of $3.20B, 142.82M shares outstanding, 232 institutional holders tracked. Key dilution vectors include approximately 24 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
32
💰 Cash Runway
10
📊 Float Risk
7
⚠️ Warrant Exposure
15
🔄Convertible Debt

🌦️ Dilution Forecast

☀️
Clear
No significant dilution signals
0%
No significant dilution signals detected for DYN.
🔔 Track DYN — Get forecast alerts →

💹 Market Data

Market Cap$3.20B
Shares Outstanding142.82M
FloatN/A
Cash$753.10M
Debt$9.94M
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 22.2% shares (2026Q1 vs prior)
232 institutional holders · 223.20M shares
#1 T. Rowe Price Investment Management, Inc. 30.79M shares
#2 JANUS HENDERSON GROUP PLC 27.29M shares
#3 VANGUARD CAPITAL MANAGEMENT LLC 12.81M shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest22.30M
Days to Cover8.0
% of FloatN/A
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

No recent SEC insights

📰 Recent News

No recent news

📋 What This Means for DYN Shareholders

Dyne Therapeutics, Inc. (DYN) has a DilutionScore of 17/100, rated Low dilution risk. At this score level, DilutionWatch's real-time EDGAR monitoring shows limited near-term dilution signals. This does not mean zero dilution risk — shelf registrations can be filed and activated quickly — but the current filing profile shows no major outstanding dilution programs. Score as of July 14, 2026.

DilutionWatch's EDGAR monitoring for DYN shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for DYN in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for DYN alongside comparable low-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track DYN Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking DYN — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — LOW Risk

Other LOW dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for DYN
📊 DYN FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 DYN Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.